Today: 14 March 2026
Subscribe
Browse Category

NASDAQ:NAMS 11 October 2025 - 5 January 2026

NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS

NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS

NewAmsterdam Pharma shares fell about 5% to $33.42 in afternoon trading Monday after two insiders filed Form 144 notices for proposed stock sales tied to RSU vesting. CFO M. Ian Somaiya and CSO Johannes Kastelein flagged plans to sell a combined 11,118 shares. The stock touched an intraday low of $32.68. Biotech stocks broadly lagged the market ahead of Friday’s U.S. jobs report.
5 January 2026
·
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma shares jumped 12.3% to $37.05 on Oct. 10, 2025, hitting a new 52-week high and valuing the company at $4.2 billion. Its lead drug, obicetrapib, showed a 21% drop in major cardiovascular events and lowered Alzheimer’s biomarkers in Phase 3 trials. The EMA is reviewing marketing applications; a key U.S. trial will read out in 2026. The firm ended Q2 with $783.3 million in cash.
11 October 2025

Stock Market Today

  • Parex Resources (TSX:PXT) Seen Slightly Overvalued Despite Recent Strong Gains
    March 14, 2026, 4:15 PM EDT. Parex Resources (TSX:PXT) shares surged about 24% over the past month and over 110% over the year, drawing attention to its current valuation. Despite the strong price momentum, analysts place the stock at a fair value near CA$24.74, slightly below the latest price of about CA$26.08, suggesting a 5.4% overvaluation. Consensus price targets hover around CA$17.17, reflecting cautious expectations for revenue and earnings growth through 2028. The divergence between traditional valuation models and discounted cash flow (DCF) estimates-one indicating undervaluation and the other mild overvaluation-creates uncertainty about true value. Investors should consider regulatory risks in Colombia and potential costs to sustain production levels when assessing Parex's outlook.
Go toTop